Evidence map›Paper›PMID 42108344›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Production of Bispecific Antibody Fragments from Fc Fusion.

Ryutaro Asano

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Ryutaro AsanoDepartment of Biotechnology and Life Science, Graduate School of Engineering, Tokyo University of Agriculture and Technology, 2-24-16 Naka-cho, Koganei, Tokyo, 184-8588, Japan. ryutaroa@cc.tuat.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bispecific antibody (BsAb) fragments, such as bispecific tandem single-chain Fv and bispecific diabodies, have a convenient size for rapid tissue penetration and high target retention. Their smaller size also allows them to be expressed in cost-effective microorganisms. However, the production of BsAb fragments using Escherichia coli is often hampered by their expression as insoluble aggregates. In addition, BsAb fragments generally require the fusion of affinity peptide tags, which might negatively impact molecular folding and function and increase immunogenicity, as most of these tags are derived from non-human sequences. The production of BsAb fragments from their Fc fusion with a protease recognition site inserted around the hinge region is an ideal strategy. Protein A purification can be applied to Fc fusion proteins, and BsAb fragments can be prepared by protease digestion. Papain is also applicable for preparing BsAb fragments from Fc fusion; however, undesired digestion due to low sequence specificity is sometimes a problem. Herein, a method using a human rhinovirus 3C protease recognition site is presented as an example of the production of BsAb fragments from Fc fusion.

Indexed as

Antibodies, BispecificImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsEscherichia coliHumansProtein EngineeringAntibodies, BispecificImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsBispecific antibody fragmentBispecific diabodyBispecific tandem scFvFc fusionProtease digestion

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.